Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results Meeting Abstract
| Authors: | Gutierrez, M.; Friedman, C. F.; Long, G. V.; Ascierto, P. A.; Melero, I.; Richards, D.; Bastos, B. R.; Moreno Garcia, V.; Uemura, M.; Conkling, P.; Corr, B. R.; Kim, A. M.; Zhu, L.; Hammell, A.; Perumal, D.; Chouzy, A.; Benavente, F.; Awosemo, O.; Hannah, A.; Le, D. T. |
| Abstract Title: | Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S882 |
| Language: | English |
| ACCESSION: | WOS:000866211601012 |
| DOI: | 10.1016/j.annonc.2022.07.866 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 740P -- Source: Wos |
